Although mutations in SPRED1 and KIT are relatively weaker activators of the RAS pathway compared to the BRAFV600E or NRASQ61R mutants, they frequently occur together to drive mucosal melanoma (Ablain et al., 2018). Here, SPRED1 is linked to melanoma.